Metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from a large tertiary centre in Kenya

Clinical Microbiology and Infection

Volumn 14, Issue 8, 2008, Pages 755-759

  Pitout, Johann D D ^a,e   Revathi, G ^b   Chow, B L ^a   Kabera, B ^b   Kariuki, S ^c   Nordmann, P ^d   Poirel, L ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b AGA KHAN UNIVERSITY   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d BICÊTRE HOSPITAL   (France)

^e CALGARY LABORATORY SERVICES   (Canada)

Author keywords

Kenya; Metallo lactamases; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE VIM 2; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENZYME SYNTHESIS; EPIDEMIC; GENE SEQUENCE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; INTENSIVE CARE UNIT; KENYA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; TERTIARY HEALTH CARE;

PSEUDOMONAS AERUGINOSA;

EID: 48449083640     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02030.x     Document Type: Article

References (22)

1. Poirel L, Pitout JD, Nordmann P. Carbapenemases: Molecular diversity and clinical consequences. Future Microbiol 2007; 2: 501-512.
2. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.
3. Gupta V. Metallo-β-lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs 2008; 17: 131-143.
4. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-331.
5. Laupland KB, Parkins MD, Church DL et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: Importance of metallo-β-lactamase (MBL)-producing strains. J Infect Dis 2005; 192: 1606-1612.
6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement M100-S14. Wayne, PA: NCCLS, 2004.
7. Pitout JD, Gregson DB, Poirel L et al. Detection of Pseudomonas aeruginosa producing metallo-β-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43: 3129-3135.
8. Pitout JD, Chow BL, Gregson DB et al. Molecular epidemiology of metallo-β-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region: Emergence of VIM-2-producing isolates. J Clin Microbiol 2007; 45: 294-298.
9. Corvec S, Poirel L, Espaze E et al. Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme. J Hosp Infect 2008; 68: 73-82.
10. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
11. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(suppl 2): S43-S48.
12. Poirel L, Naas T, Nicolas D et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44: 891-897.
13. Aubron C, Poirel L, Fortineau N et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-β-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 2005; 11: 254-259.
14. Ktari S, Arlet G, Mnif B et al. Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo-β-lactamase, CTX-M-15 extended-spectrum β-lactamase, and CMY-4 AmpC β-lactamase in a Tunisian university hospital. Antimicrob Agents Chemother 2006; 50: 4198-4201.
15. Ozgumus OB, Caylan R, Tosun I et al. Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-β-lactamase gene in a university hospital in Turkey. Microb Drug Resist 2007; 13: 191-198.
16. Huang YT, Chang SC, Lauderdale TL, Yang AJ, Wang JT. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa carrying metallo-β-lactamase genes in Taiwan. Diagn Microbiol Infect Dis 2007; 59: 211-216.
17. Livermore DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-2048.
18. Conejo MC, Garcia I, Martinez-Martinez L, Picabea L, Pascual A. Zinc eluted from siliconized latex urinary catheters decreases OprD expression, causing carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2003; 47: 2313-2315.
19. Pena C, Suarez C, Tubau F et al. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital: Clinical and epidemiological implications. Clin Microbiol Infect 2007; 13: 1026-1029.
20. Lee YC, Ahn BJ, Jin JS et al. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea. J Microbiol 2007; 45: 358-363.
21. Zavascki AP, Barth AL, Goncalves AL et al. The influence of metallo-β-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J Antimicrob Chemother 2006; 58: 387-392.
22. Zavascki AP, Barth AL, Fernandes JF et al. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: A prospective observational study. Crit Care 2006; 10: R114.